Ezra Cohen to Patient Selection
This is a "connection" page, showing publications Ezra Cohen has written about Patient Selection.
Connection Strength
0.570
-
Selection of Head and Neck Cancer Patients for Intensive Therapy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):157-166.
Score: 0.130
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 07 15; 7(1):184.
Score: 0.128
-
Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov; 29(11):925-34.
Score: 0.080
-
Personalizing cancer care: updates on head and neck cancer. Expert Rev Anticancer Ther. 2009 Sep; 9(9):1219-22.
Score: 0.065
-
Forthcoming receptor tyrosine kinase inhibitors. Expert Opin Ther Targets. 2006 Dec; 10(6):793-7.
Score: 0.053
-
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65.
Score: 0.052
-
Patient selection for immunotherapy in head and neck cancer - Authors' reply. Lancet Oncol. 2021 07; 22(7):e291-e292.
Score: 0.037
-
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271.
Score: 0.027